Epidemiological survey of haemophiliacs with inhibitors in France: orthopaedic status, quality of life and cost--the 'Statut Orthopédique des Patients Hémophiles' avec Inhibiteur study.
The physical condition of severe haemophilia and the impact of advances in replacement therapy have been much studied, but little work has been done on patients who developed inhibitors. The 'Statut Orthopédique des Patients Hémophiles avec Inhibiteur' study was conducted in France in order to assess the orthopaedic status and quality of life of such patients, and the cost of their medical management. Fifty haemophiliacs aged 12-63 years with a history of high-responder inhibitors were included. Clinical assessment showed that only 12% of the patients had a nil pain score and 2% a nil clinical score, as per Gilbert scale. The mean clinical score was significantly higher in patients over 35 years of age than in younger ones. However, younger patients appeared to have a more impaired orthopaedic status than young haemophiliacs without inhibitors of similar age in previous published cohorts. Surprisingly, older haemophiliacs tended to have the best mental quality of life, contrasting with their highly impaired orthopaedic condition and physical quality of life. The mean cost of clinical resources consumed during the year preceding enrolment was Euro 268 999, 99% of which was related to clotting factor. Marked between-patient differences in cost were noted. Our study suggests that the management of haemophiliacs with inhibitors should be improved in order to prevent haemophilic arthropathy to an extent similar to that of patients without inhibitors. Cost-benefit assessment of any therapeutic strategy should always be combined with quality-of-life evaluation.
Stieltjes
Natalie
N
Centre des hémophiles, Hôpital Cochin, Paris, France. natalie.stieltjes@cch.aphp.fr
Torchet
Marie F
MF
Misrahi
Laure
L
Roussel-Robert
Valérie
V
Lambert
Thierry
T
Guérois
Claude
C
Bertrand
Marie A
MA
Briquel
Marie E
ME
Borel-Derlon
Annie
A
Dirat
Gérard
G
D000293:Adolescent; D000328:Adult; D000368:Aged; D019774:Blood Coagulation Factor Inhibitors / Q000191:economics / Q000627:therapeutic use; D002648:Child; D003362:Cost-Benefit Analysis; D003430:Cross-Sectional Studies; D005164:Factor IX / Q000037:antagonists & inhibitors / Q000191:economics / Q000627:therapeutic use; D005169:Factor VIII / Q000037:antagonists & inhibitors / Q000191:economics / Q000627:therapeutic use; D005260:Female; D005602:France / Q000453:epidemiology; D017048:Health Care Costs; D006467:Hemophilia A / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology* / Q000523:psychology; D002836:Hemophilia B / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology* / Q000523:psychology; D006801:Humans; D008297:Male; D008875:Middle Aged; D019637:Orthopedic Procedures; D011788:Quality of Life; D016896:Treatment Outcome; D055815:Young Adult
D019774:Blood Coagulation Factor Inhibitors; D005169:Factor VIII; D005164:Factor IX